Braeburn

First Wave of Healthcare Providers Being Trained in 55 Cities over the Next Six Weeks Probuphine Will Be Available to Patients in June 2016 PRINCETON, N.J. — May 31, 2016—Braeburn Pharmaceuticals announces plans to make Probuphine available to healthcare providers and patients in June, immediately following Food and Drug Administration (FDA) approval on May 26, […]

Patients and Providers Have a New Option to Combat Opioid Dependence PRINCETON, N.J.—May 26, 2016—Braeburn Pharmaceuticals announces that the U.S. Food & Drug Administration (FDA) approved Probuphine, the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically 8 mg or less per […]

Company Will Stay and Fight for Civil Rights and Diversity Princeton, New Jersey— May 17, 2016—Braeburn Pharmaceuticals, developer of medications for opioid addiction and other chronic neurological diseases, will proceed with plans to develop a manufacturing and research facility in Durham County, North Carolina, despite the enactment of HB2, the controversial law that overturns local […]

Princeton, New Jersey and Lund, Sweden — 11 May, 2016 — Braeburn Pharmaceuticals and Camurus today announce top line results of a multiple-dose, pivotal Phase 2 study assessing the blockade by CAM2038 of subjective opioid effects of multiple randomized hydromorphone challenges in adults with opioid use disorder. A key objective of medication-assisted treatment for opioid […]